My watch list
my.bionity.com  
Login  

Viruses, Vol. 10, Pages 351: Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy

Viruses, Vol. 10, Pages 351: Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy

Viruses doi: 10.3390/v10070351

Authors: Frank Oechslin

Bacteriophage (phage) therapy, i.e., the use of viruses that infect bacteria as antimicrobial agents, is a promising alternative to conventional antibiotics. Indeed, resistance to antibiotics has become a major public health problem after decades of extensive usage. However, one of the main questions regarding phage therapy is the possible rapid emergence of phage-resistant bacterial variants, which could impede favourable treatment outcomes. Experimental data has shown that phage-resistant variants occurred in up to 80% of studies targeting the intestinal milieu and 50% of studies using sepsis models. Phage-resistant variants have also been observed in human studies, as described in three out of four clinical trials that recorded the emergence of phage resistance. On the other hand, recent animal studies suggest that bacterial mutations that confer phage-resistance may result in fitness costs in the resistant bacterium, which, in turn, could benefit the host. Thus, phage resistance should not be underestimated and efforts should be made to develop methodologies for monitoring and preventing it. Moreover, understanding and taking advantage of the resistance-induced fitness costs in bacterial pathogens is a potentially promising avenue.

Authors:   Oechslin, Frank
Journal:   Viruses
Volume:   10
edition:   7
Year:   2018
Pages:   351
DOI:   10.3390/v10070351
Publication date:   30-Jun-2018
Facts, background information, dossiers
More about Molecular Diversity Preservation International
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE